For the Inventor, By the Inventor

Enter assignee name

Aventis Pharma S.a.

USPTO Granted Patents = 377

CIPO Patents = 13

EPO Patents = 69

Trademarks = 10

Forward Citations = 2,636

Loading Chart...

Loading Chart...

601 inventors (with patents filed for the assignee):

Serge Mignani (29 out of 69 patents)

Eric Bacque (24 out of 31 patents)

Michel Tabart (22 out of 43 patents)

4. Jean-Christophe Carry (21 out of 45 patents)

5. Marie-Christine Bissery (18 out of 22 patents)

6. Jean Bouquerel (17 out of 22 patents)

7. Dominique Lesuisse (16 out of 24 patents)

8. Augustin Hittinger (15 out of 17 patents)

9. Baptiste Ronan (15 out of 32 patents)

10. Michel Perricaudet (14 out of 38 patents)

11. Patrick Mailliet (14 out of 23 patents)

12. Jean-Luc Malleron (14 out of 32 patents)

13. Fabrice Viviani (14 out of 22 patents)

14. Jean-Claude Barriere (14 out of 28 patents)

15. Bruno Filoche (13 out of 17 patents)

Core Competencies:

Dimethoxy Docetaxel

Cabazitaxel

Parkin Gene Mutations

Pyrazolyl Derivatives

Telithromycin

Neurodegenerative Diseases

VEGF-Inhibiting Agents

Recombinant Adenoviruses

Steroid Derivatives

Oligosaccharide Mixtures

Kinase Inhibitors

Antitumor Combinations

377 patents: Sort by Forward Citations

1. 10160739 - Crystalline forms of dimethoxy docetaxel and methods for preparing the same (2018-12-25),

2. 9540693 - Mutations of the parkin gene, compositions, methods and uses (2017-01-10),

3. 9309210 - Crystalline form of cabazitaxel and process for preparing the same (2016-04-12),

4. 9126969 - Pyrazolylbenzimidazole derivatives, compositions containing them and use thereof (2015-09-08),

5. 8962021 - Solid pharmaceutical composition comprising telithromycin (2015-02-24),

6. 8927592 - Antitumoral use of cabazitaxel (2015-01-06),

7. 8852878 - Method for identifying an antagonist of guanine nucleotide releasing factor 1 (2014-10-07),

8. 8846959 - Crystalline forms of dimethoxy docetaxel and methods for preparing the same (2014-09-30),

9. 8835618 - Mutations of the parkin gene (2014-09-16),

10. 8709426 - Nucleotide sequence coding for variable regions of β chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses (2014-04-29),

11. 8685705 - Desmosterol-producing yeast strains and uses thereof (2014-04-01),

12. 8642028 - Recombinant adenoviruses encoding the specific iodine transporter (NIS) (2014-02-04),

13. 8608961 - Method for affinity chromatography of antithrombin III (2013-12-17),

14. 8492610 - Transgeneic animal expressing a multiple mutated form of presenilin 1 (2013-07-23),

15. 8481589 - Taxoid-based compositions (2013-07-09),

AVENTIS PHARMA S.A. is a leading global pharmaceutical company that specializes in the research, development, manufacturing, and marketing of innovative healthcare products. With a strong commitment to improving health and well-being, AVENTIS PHARMA S.A. strives to provide effective and safe medications to patients around the world. The company's diverse portfolio includes prescription medicines, vaccines, and consumer healthcare products. With a strong focus on research and development, AVENTIS PHARMA S.A. continues to drive innovation in the pharmaceutical industry.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

377 Patents

#1 in Antony

#64 in France

#2,370 in the World

Aventis Pharma S.a.

Forward Citations = 2,636

601 inventors:

Serge Mignani (29 out of 69 patents)

Eric Bacque (24 out of 31 patents)

Michel Tabart (22 out of 43 patents)

4. Jean-Christophe Carry (21 out of 45 patents)

5. Marie-Christine Bissery (18 out of 22 patents)

Please report any incorrect information to support@idiyas.com

Loading…